```html

Impetigo contagiosa – A Comprehensive Medical Guide

Overview

Impetigo contagiosa, commonly called impetigo, is a highly contagious superficial bacterial skin infection. It typically affects the epidermis and sometimes the upper layers of the dermis, producing red sores that quickly rupture, ooze, and develop a characteristic honey‑colored crust.

• Age group: Most cases occur in children ages 2–5 years, but adolescents and adults can be affected, especially in crowded or humid environments.
• Prevalence: In the United States, impetigo accounts for about 2–5% of all pediatric dermatology visits. Worldwide, incidence is highest in low‑to‑middle‑income countries where hygiene and crowding increase spread (WHO, 2023).
• Geography: Warm, humid climates (e.g., the southeastern U.S., parts of Africa, and Southeast Asia) see higher rates, but outbreaks occur globally.

Symptoms

Impetigo presents in two classic patterns—non‑bullous (crusted) and bullous (vesicular). The disease may start with a single lesion that spreads to adjacent skin.

Non‑bullous (crusted) impetigo

• Red papules or pustules: Small, itchy bumps that become filled with yellow‑white pus.
• Honey‑colored crusts: After the lesion ruptures, a thick, yellow‑brown crust forms, often described as “pearly” or “golden.”
• Location: Typically around the nose, mouth, and eyelids, but can spread to any area.
• Swelling and tenderness: Mild edema may surround the lesions.

Bullous impetigo

• Fluid‑filled blisters: Larger, translucent vesicles that break easily.
• Thin, painless crust: After rupture, a thin, yellow crust remains, often called “the honey‑dew crust.”
• Location: More common on the trunk, extremities, and diaper area in infants.

General symptoms (both types)

• Itching or mild burning sensation.
• Secondary bacterial infection (e.g., cellulitis) causing increased redness, warmth, and pain.
• Fever is uncommon (<5% of cases) but may appear if infection spreads.
• Swollen lymph nodes near the affected area can develop.

Causes and Risk Factors

Impetigo is caused by bacteria that normally live on the skin or in the nose.

Microorganisms

• Staphylococcus aureus (including methicillin‑resistant strains, MRSA) – responsible for ~70% of cases, especially the bullous form.
• Streptococcus pyogenes (group A β‑hemolytic streptococcus) – more often linked to the non‑bullous type.

Risk factors

• Age: Young children have immature skin barriers and are more prone to scratching.
• Skin disruption: Cuts, insect bites, eczema, impetigo scars, or other dermatitis provide entry points.
• Close contact: Day‑care centers, schools, sports teams, and households with shared towels or clothing.
• Warm, humid environment: Promotes bacterial growth.
• Immunocompromised state: HIV, chemotherapy, or chronic steroid use.
• Poor hygiene: Inadequate hand‑washing increases transmission.

Diagnosis

Diagnosis is largely clinical, based on the appearance and distribution of lesions. However, certain situations require laboratory confirmation.

Clinical assessment

• Visual inspection of the characteristic crusts and blisters.
• History of recent exposure to infected individuals or skin trauma.

Laboratory tests

• Gram stain & culture: Swab of lesion exudate to identify the specific bacteria and antibiotic sensitivities—crucial for suspected MRSA or treatment failures.
• Rapid antigen detection test (RADT): Occasionally used for streptococcal identification.
• Blood tests: Rarely needed; may be ordered if systemic infection is suspected (elevated white blood cell count, CRP).

Differential diagnosis

Conditions that can mimic impetigo include eczema, allergic contact dermatitis, herpes simplex, fungal infections (tinea), and varicella. Accurate diagnosis prevents inappropriate therapy.

Treatment Options

Therapy aims to eradicate the bacteria, relieve symptoms, and prevent spread.

Topical antibiotics

• Mupirocin 2% ointment: First‑line for limited disease (<5 lesions). Apply to clean skin three times daily for 5–7 days.
• Retapamulin 1% ointment: Alternative for patients with mupirocin intolerance.

Oral antibiotics

Systemic therapy is recommended when:

• Lesions cover a large surface area (>5% body surface).
• Rapid spread or presence of bullous impetigo.
• Suspected MRSA or failure of topical therapy.

Common regimens (7–10 days):

• Cephalexin 500 mg q6h (or dicloxacillin) – effective against MSSA and streptococci.
• Clindamycin 300 mg q6h – covers MRSA, but beware of C. difficile risk.
• Trimethoprim‑sulfamethoxazole (TMP‑SMX) 160/800 mg bid – MRSA‑directed.
• For severe or invasive disease, IV vancomycin or cefazolin may be required.

All antibiotics should be taken for the full prescribed duration, even if lesions improve early.

Supportive measures

• Gentle cleansing with mild soap and water twice daily.
• Application of a non‑adherent dressing (e.g., bacitracin‑free gauze) to protect ruptured lesions.
• Antihistamines (e.g., cetirizine) for itching if needed.

When procedural intervention is needed

• Incision and drainage are rarely required for impetigo but may be necessary if an associated abscess develops.

Living with Impetigo contagiosa

Even after treatment begins, daily habits can speed recovery and limit spread.

Hygiene practices

• Wash hands with soap and water for at least 20 seconds after touching lesions.
• Use separate towels, washcloths, and bedding for the affected person.
• Keep fingernails trimmed to reduce scratching and secondary infection.

Clothing and environment

• Dress the child in loose, breathable cotton garments.
• Change clothing and linens daily; launder in hot water (≥60 °C) with detergent.
• Avoid sharing personal items (toys, sports equipment, water bottles).

School and childcare

• Children can usually attend school once 24 hours of appropriate antibiotic therapy have elapsed and lesions are covered.
• Notify caregivers or teachers about the diagnosis so they can reinforce hand‑washing.

Monitoring recovery

• Expect visible improvement within 2–3 days of starting antibiotics.
• If new lesions appear after a week of treatment, contact a healthcare provider for possible culture‑directed therapy.
• Document any side effects (e.g., rash, gastrointestinal upset) and report promptly.

Prevention

Because impetigo spreads easily, prevention focuses on barrier protection and hygiene.

• Hand hygiene: Wash hands frequently, especially after diaper changes, sports, or touching an animal.
• Skin care: Keep minor cuts, abrasions, and eczema moisturized and covered.
• Avoid sharing: Towels, clothing, razors, and personal care items should be individual.
• Environmental cleaning: Disinfect surfaces (e.g., gym equipment, bathroom fixtures) with a bleach‑based solution (1 % sodium hypochlorite).
• Prompt treatment of other skin infections: Early antibiotic therapy for cellulitis or infected eczema reduces the reservoir of bacteria.

Complications

While most cases resolve without lasting issues, untreated or severe impetigo can lead to:

• Cellulitis: Deeper skin infection causing extensive redness, swelling, and pain.
• Post‑streptococcal glomerulonephritis (PSGN): A rare immune‑mediated kidney inflammation after streptococcal impetigo (incidence <1 % in developed countries, higher in some low‑income settings) — characterized by hematuria, edema, and hypertension.
• Scar formation: Particularly after bullous impetigo or if lesions are repeatedly scratched.
• Ecthyma: Deep ulcerating lesions that may require surgical debridement.
• Systemic infection: Bacteremia or sepsis is uncommon but can occur in immunocompromised individuals.

When to Seek Emergency Care

Key Take‑aways

• Impetigo contagiosa is a common, highly contagious bacterial skin infection, especially in young children.
• Typical lesions are red papules that burst and form honey‑colored crusts (non‑bullous) or fluid‑filled blisters (bullous).
• Diagnosis is primarily clinical; cultures are reserved for extensive disease or treatment failure.
• Topical mupirocin for limited disease; oral antibiotics for widespread or bullous forms.
• Good hygiene, separate linens, and prompt treatment are essential to curb spread.
• Complications are rare but can be serious; seek care if lesions worsen or systemic signs appear.

References: Mayo Clinic. Impetigo. 2023. | CDC. Impetigo – Treatment & Prevention. 2022. | WHO. Impetigo Fact Sheet. 2023. | NIH National Library of Medicine. Staphylococcus aureus skin infections. 2021. | Cleveland Clinic. Impetigo in Children. 2024.

```